Humanized antibodies

Details Humanized antibodies Humanized antibodies

2005-03-29

2005-03-29

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S137100, C424S141100, C530S388100

Reexamination Certificate

active

06872392

ABSTRACT:
Chimeric human antibody expression vectors are constructed by inserting the heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2respectively into an expression vector which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured to produce a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but show a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

REFERENCES:
patent: 5585089 (1996-12-01), Queen et al.
patent: 5830470 (1998-11-01), Nakamura et al.
patent: 5939532 (1999-08-01), Nakamura et al.
patent: 6042828 (2000-03-01), Nakamura et al.
patent: 0 314 161 (1989-05-01), None
patent: 0 533 199 (1993-03-01), None
patent: 9 109 967 (1991-07-01), None
Barker et al., “Effect of a Chimeric Anti-Ganglioside GD2Antibody on Cell-mediaed Lysis Human Neuroblastoma Cells”, Cancer Research, vol. 51, Jan. 1991, pp. 144-149.
Liu et al., “Expression of Mouse: Human Immunoglobulin Heavy-Chain cDNA in Lymphoid Cells”, Gene, vol. 54, No. 1, Jul. 1987, pp. 33-40.
Irie et al., “Human Monoclonal Antibody to Ganglioside GM2 for Melanoma Treatment”, reprinted from The Lancet, pp. 786-787 (1989).
LoBuglio et al., “Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response”, Prod. Natl. Acad. Sci, USA 86:4220-4224 (1989).
Morrison et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”, Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984).
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse”, Nature 231:522-525 (1986).
Hakimi et al., “Reduced Immunogenicity an Improved Pharmacokinetics of Human anti-Tac In Cynomolgus Monkeys”, The Journal of Immunology 147(4): 1352-1359 (1991).
Mueller et al., “Enhancement of Antibody-Dependent Cytotoxicity witha a Chimeric Anti-GD2 Antibody”; The Journal of Immunology, 144(4):1382-1386 (1990).
Bernstein et al., “Monoclonal Antibody Therapy of Mouse Leukemia”, Kenneth R.H. Editor, Monoclonal Antibodies, Plenium Press, New York, pp. 275-291 (1980).
Hakomori, “Aberrant Glycosylation in Cancer Cell Membranes as Focused on Glycolipids: Overview and Perspectives”, Cancer Research 45:2405-2414 (1985).
Natoli et al., A Murine Monoclonal Antibody Detecting N-Acetyl-and-Glycolyl-GM2: Charaterization of Cell Surface Reactivity, Cancer Research 46:4116-4120 (1986).
Tai et al., “Ganglioside GM2 as a human tumor antigen (OFA-I-1)”, Proc. Natl., Acad. Sci. USA 50:5392-5396 (1983).
Miyake et al., Generation of Two Murine Monoclonal Antibodies That Can Discriminate N-Glycol and N-Acetyl Neuraminic Acid residues of GM2Gangliosides, Cancer Research 48: 6154-6160 (1988).
Fredman et al., “A New Ganglioside of the Lactotertraose Series, GaINAC-3'isolM1Detected in Human Meconium”, The Journal of Biological Chemistry 264(12): 12122-12125 (1989).
Miyaji et al., “Expression of human beta-interferon in Namalwa KJM-1 wa adapted to serum-free medium”, Cytotechnology 3: 133-140 (1990).
Kuwana et al., “Expression of Chimeric receptor Composed of Immunoglobulin-Derived V Regions and T-Cell Receptor-Derived C Regions”, Biochemical and Biophysical Research Communications, 149(3):960-968 (1987).
Hamer et al., “SV40 Recombinants Carrying a Functional RNA Splice Junction an Polyadenylation Site from the chromosomal Mouseimg id="CUSTOM-CHARACTER-00001" he="2.46mm" wi="3.56mm" file="US06872392-20050329-P00001.TIF" alt="custom character" img-content="character" img-format="tif" ?majGlobin Gene,” Cell 17:737-747 (1979).
Page et al., “High Level Expression of the Humanized Monoclonal Antibody Campath-1H in Chinese Hamster Ovary Cells”, Bio/Technology 9:64-68 (1991).
Saul et al., “Preliminary Refinement and Structural Analysis of the Fab Fragment from Human Immunoglobulin New at 2.0Åresolution”, The Journal of Biological Chemistry 253(2):585-597 (1978).
Riechmann et al., Reshaping human antibodies for therapy:, Nature 332: 323-327 (1988).
Epp et al., “Crystal and Molecular Structure of a Dimer Composed of the Variable Portions of the Bence-Jones Protein REI”, Eur. J. Biochem. 45:513-524 (1974).
Emery et al., Expert Opinion on Investigational Drugs, vol. 3(3):241-251, Mar. 1994.
Morrison and Ol, Advances in Immunology 44:65-92, 1989.
and Morrison et al, Biotechniques vol. 4: pp 214-221, 1986.
Halcomon in “Monoclonal Antibodies and Functional Cell Lines”, Kennett et al., Ed., Plenum Press 67-100, 1985.
Osband et al, (Immunology Today, vol. 111, No. 6, 1990 pp 193-195).
Harris et al. Tibtech 11:42-44, 1993.
Berek et al; (Cell; vol. 67 pp 1121-1129).

Affiliated with

Also associated with

Rating

Humanized antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Humanized antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3447525